Geri Besleme Yoluna Yerleştirilen Denetleyici

Esta pesquisa demonstrou que, nas condições estudadas, o parecoxibe determinou maior quantidade de necrose, menor quantidade de apoptose e maior quantidade de células viáveis nos rins dos ratos submetidos ou não à hemorragia aguda.

Esses resultados, que podem contribuir para geração de conhecimentos relacionados a esta classe de medicamentos, prudente notar-se, também podem ter trazido novas questões.

A literatura mostra resultados conflitantes relacionados com o uso de COXIBEs e proteção renal, talvez pela diversidade metodológica. Este estudo, dentro das condições estabelecidas, sugere tendência ao benefício do uso do fármaco em relação à proteção renal.

Entretanto, esta pesquisa focou os critérios morfológicos da morte celular, e este tipo de classificação tem sido muito estudado recentemente por pesquisadores, inclusive, novas classificações sendo continuamente propostas. Desse modo, em futuro próximo, pode ser que os critérios morfológicos aqui estudados não sejam os mais acurados para entender a dinâmica da proteção relacionada com esta classe de medicamentos.

Além desta questão taxonômica, este estudo apresentou limitação quanto à determinação das vias de apoptose relacionadas com a proteção evidenciada. Isso pode ser algo sensato a ser considerado, pois, na identificação da via (e suas cascatas) podem- se criar modos de focalizar a terapia ou a proteção, sem demais prejuízos.

No sentido da anatomia, conhecem-se sítios renais específicos para as afecções – túbulos, medula, vasos e células corticais intersticiais. Neste estudo, como o rim foi visto como um todo, o método não contemplou os sítios anatômicos relacionados com os padrões morfológicos de morte celular, e esta questão também permanece aberta.

Um ponto intrigante pode ser a relação temporal entre inflamação, uso do medicamento e análise da citometria de fluxo. Será que a prevenção da apoptose significou verdadeiro salvamento da morte celular, ou será que simplesmente ocorreu um atraso da sinalização apoptótica? Esta questão prudentemente deve ser levantada.

Além de tudo, o entendimento da biologia molecular está cada vez mais presente na ciência moderna. Assim, considerar o estudo das proteínas relacionadas com dano ou proteção também pode ser algo a se pesquisar. Métodos de avaliação de proteínas, como Western Blot, ou análises de imagens de microscopia eletrônica no intuito de observar os fosfolipídeos sinalizadores de apoptose podem ser caminhos científicos futuros.

De qualquer modo, com a criação de pequenas evidências, são possíveis novas questões no sentido de trazer maiores benefícios para esta e próximas gerações, e assim a dinâmica da ciência estabelece-se e perpetua-se.

7 CONCLUSÃO

Em rins de ratos analisados por citometria de fluxo, independentemente de os animais terem sido submetidos à hemorragia, a dose única de parecoxibe gerou maior quantidade de necrose, menor quantidade de apoptose e maior quantidade de células viáveis.

8 REFERÊNCIAS

Akcay A, Nguyen Q, Edelstein CL. Mediators of inflammation in acute kidney injury. Mediators Inflamm. 2009; 2009:137072.

Ayala A, Perrin MM, Meldrum DR, Ertel W, Chaudry IH. Hemorrhage induces an increase in serum TNF which is not associated with elevated levels of endotoxin. Cytokine. 1990;2(3):170-4.

Bach PH, Nguyen TK. Renal papillary necrosis – 40 years on. Toxicol Pathol. 1998;26(1):73-91.

Batlouni M. Anti-Inflamatórios Não Esteroides: Efeitos Cardiovasculares, Cérebro- Vasculares e Renais. Arq Bras Cardiol. 2010;94(4):556-63.

Bertho AL, Santiago MA, Coutinho SG. Flow citometry in study of cell death. Mem Inst Oswaldo Cruz. 2000;95(3):429-33.

Black HE. Renal toxicity of non-steroidal antiinflammatory drugs. Toxicol Pathol. 1986;14(1):83-90.

Bonegio R, Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens. 2002;11(3):301-8.

Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int. 2004;66(2):480-5.

Caetano AM, Vianna Filho PT, Castiglia YM, Golim MA, de Souza AV, de Carvalho LR, Deffune E, de Oliveira C, Vianna PT. Erythropoietin attenuates apoptosis after ischemia-reperfusion-induced renal injury in transiently hyperglycemic Wistar rats. Transplant Proc. 2011;43(10):3618-21.

Cerella C, Sobolewski C, Chateauvieux S, Henry E, Schnekenburger M, Ghelfi J, Dicato M, Diederich M. COX-2 inhibitors block chemotherapeutic agent-induced apoptosis prior to commitment in hematopoietic cancer cells. Biochem Pharmacol. 2011;82(10):1277-90.

Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med. 2000;29(3-4):323-33.

Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs. 2001;61(8):1133-41.

Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des. 2005;11(14):1795-804.

Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 1984;310(9):563-72.

Curi PC. Metodologia e Análise da Pesquisa em Ciências Biológicas. Botucatu: Gráfica e Editora Tipomic; 1997.

Curtis FG. Sevoflurano e dexmedetomidina em isquemia e reperfusão renais no rato [Tese]. Botucatu: Faculdade de Medicina de Botucatu, Universidade Estadual Paulista "Júlio de Mesquita Filho"; 2008.

Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M. Aspirin and nonsteroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501–7.

de Souza Silva M, Castiglia YM, Vianna PT, Viero RM, Braz JR, Cassetari ML. Rat model of depending prostaglandin renal state: effect of ketoprofen.Ren Fail. 2006;28(1):77-84.

Diego LA, Marques CD, Vianna PT, Viero RM, Braz JR, Castiglia YM. Glibenclamide effects on renal function and histology after acute hemorrhage in rats under sevoflurane anesthesia. Ren Fail. 2007;29(8):1039-45.

Donnahoo KK, Shames BD, Harken AH, Meldrum DR. Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol. 1999;162(1):196-203.

El-Awady RA, Saleh EM, Ezz M, Elsayed AM. Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells. Toxicol Appl Pharmacol. 2011;255(3):271-86.

Elrod HA, Yue P, Khuri FR, Sun SY. Celecoxib antagonizes perifosine’s anticancer activity involving a cyclooxygenase-2-dependent mechanism. Mol Cancer Ther. 2009;8(9):2575–85.

Erni D, Banic A, Wheatley AM, Siqurdsson GH. Haemorrhage during anaesthesia and surgery: continuous measurement of microcirculatory blood flow in the kidney, liver, skin and skeletal muscle. Eur J Anaesthesiol. 1995;12 (4):423-9.

Feitoza CQ, Câmara NO, Pinheiro HS, Gonçalves GM, Cenedeze MA, Pacheco-Silva A, Santos OF. Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury. Int Immunopharmacol. 2005;5(1):79-84. Fredheim S, Borchgrevink PC, Kvarstein G. Post-operative pain management in hospitals. Tidsskr Nor Legeforen. 2011;131(18):1772-6.

Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med. 2003;253(6):643-52.

Giovanni G, Giovanni P. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects? J Nephrol. 2002;15(5):480-8.

Gluhovschi GH, Bozdog GH, Petrica L, Schiller A, Trandafirescu V, Velciov S, Gluhovschi C, Bob F. Multi-organ protection and the kidney. From nephroprotection, cardioprotection, neuroprotection to multi-organ protection. Nefrologia. 2004;24(6):519-30,532,534-5.

Guedes FS Jr, Cruz DS, Rodrigues MM, Silva LM, Amorim RL, Vianna PT, Castiglia YM. Renal histology and immunohistochemistry after acute hemorrhage in rats under sevoflurane and ketoprofen effect.Acta Cir Bras. 2012 Jan;27(1):37-42

Harris RC Jr. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol. 2002;89(6A):10D-17D.

Höcherl K, Schmidt C, Bucher M. COX-2 inhibition attenuates endotoxin-induced downregulation of organic anion transporters in the rat renal cortex. Kidney Int. 2009;75(4):373-80.

Izquierdo MC, Sanz AB, Mezzano S, Blanco J, Carrasco S, Sanchez-Niño MD, Benito- Martín A, Ruiz-Ortega M, Egido J, Ortiz A. TWEAK (tumor necrosis factor–like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney Int. 2012;81(11):1098-107.

John R, Herzenberg AM. Renal toxicity of therapeutic drugs. J Clin Pathol. 2009;62(6):505-15.

Jones P, Lamdin R. Oral cyclo-oxygenase 2 inhibitors versus other oral analgesics for acute soft tissue injury: systematic review and meta-analysis. Clin Drug Investig. 2010;30(7):419-37.

Kay MD, Brook N, Kaushik M, Harper SJ, Baqul A, Nicholson ML. Comparison of right and left laparoscopic live donor nephrectomy. BJU Int. 2006;98(4):843-4.

Komers R, Anderson S, Epstein M. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am J Kidney Dis. 2001;38(6):1145-57.

Koopman G, Reutelingsperger CP, Kuijten GA, Keehnenen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84(5):1415-20.

Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton, SA, Malorni W, Nuñez G, Peter ME, Tschopp J, Yuan J, Piacentini M, Zhivotovsky B, Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16(1):3-11. Lai MZ, Chen RH. Regulation of inflammation by DAPK. Apoptosis. 2014;19(2):357-63.

Lee HT, Ota-Setlik A, Fu Y, Nasr SH, Emala CW. Differential protective effects of volatile anesthetics against renal ischemia-reperfusion injury in vivo. Anesthesiology. 2004;101(6):1313-24.

Lee HT, Kim M, Jan M, Emala CW. Anti-inflammatory and antinecrotic effects of the volatile anesthetic sevoflurane in kidney proximal tubule cells. Am J Physiol Renal Physiol. 2006;291(1):F67-78.

Lieberthal W, Koh J, Levine S. Necrosis and apoptosis in acute renal failure. Semin Nephrol. 1998;18(5):505-18.

Lloyd R, Derry S, Moore RA, McQuay HJ. Intravenous or intramuscular parecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;(2):CD004771. Livingston A. Mechanism of action of nonsteroidal anti-inflammatory drugs.Vet Clin North Am Small Anim Pract. 2000;30(4):773-81.

McConkey D J. Biochemical determinants of apoptosis and necrosis. Toxicol Lett. 1998;99(3):157-68.

Maund E, McDaid C, Rice S, Wright K, Jenkins B, Woolacott N. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review. Br J Anaesth. 2011;106(3):292-7.

Merry AF, Jeffrey B, Souannwo O, Wilson IH, Eichhorn JH. International standards for a safe practice of anesthesia. Can J Anaesth. 2010;57(11):1027-34.

Norregaard R, Jensen BL, Li C, Wang W, Knepper MA, Nielsen S, Frokiaer J. COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction. Am J Physiol Renal Physiol. 2005;289(2):F322-33.

Nussmeier NA, Whelton AA, BrownM T, Joshi GP, Langford RM, Singla NK, Boye ME, Verburg KM. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology. 2006;104(3):518-26.

O'Donnell DH, Moloney MA, Bouchier-Hayes DJ, Lee MJ. Contrast-induced nephrotoxicity: possible synergistic effect of stress hyperglycemia. AJR Am J Roentgenol. 2010;195(1):W45-9.

Ortiz A, Justo P, Sanz A, Lorz C, Egido J. Targeting apoptosis is acute tubular injury. Biochem Pharmacol. 2003;66(8):1589-94.

Ortiz A, Sanz AB, Muñoz García B, Moreno JA, Sanchez-Niño MD, Martín-Ventura JL, Egido J, Blanco-Colio LM. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev. 2009;20(3):251-8.

Patel NS, Cuzzocrea S, Collino M, Chaterjee PK, Mazzon E, Britti D, Yagoob MM, Thiemermann C. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol. 2007;562(1-2):148-54.

Pozarowski P, Grabarek J, Darzynkiewicz Z. Flow citometry of apoptosis. Curr Protoc Cell Biol. 2004;Chapter 18:Unit 18.8.

Rizzo MT. Cyclooxygenase-2 in oncogenesis. Clin Chim Acta. 2011;412(9-10):671-87. Rosenberger C, Rosen S, Heyman SN. Renal parenchymal oxygenation and hypoxia adaptation in acute kidney injury. Clin Exp Physiol. 2006;33(10):980-8.

Rudner J, Elsaesser SJ, Müller AC, Belka C, Jendrossek V. Differential effects of anti- apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis. Biochem Pharmacol. 2010;79(1):10-20.

Salehipour M, Bahador A, Jalaeian H, Salahi H, Nikeghbalian S, Khajehee F, Malek- Hosseini SA. Comparison of right and left grafts in renal transplantation. Saudi J Kidney Dis Transpl. 2008;19(2):222-6.

Sanz AB, Sanchez-Niño MD, Ortiz A. TWEAK, a multifunctional cytokine inkidney injury. Kidney Int. 2011;80(7):708-18.

Sivarajah A, McDonald MC, Thiemermann C. The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist. J Pharmacol Exp Ther. 2005;313(2):896-901.

Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999;56:18-24.

Sinha M, Gautam L, Shukla P K, Kaur P, Sharma S, Singh TP. Current perspectives in NSAID-induced gastropathy. Mediators Inflamm. 2013;2013:258209.

Surh YJ, Kundu JK. Signal transduction network leading to COX-2 induction: a road map in search of cancer chemopreventives. Arch Pharm Res. 2005;28(1):1–15.

Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson PJ, Schwartz JI, Musliner TA, Gertz BJ, Brater DC, Yao SL. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low salt-diet. A randomized, controlled trial. Ann Intern Med. 2000;133(1):1-9.

Szabó C. Mechanisms of cell necrosis. Crit Care Med. 2005;33(12 Suppl):S530-4. Ueda N, Walker PD, Hsu SM, Shah SV. Activation of a 15-kDa endonuclease in hypoxia/reoxygenation injury without morphologic features of apoptosis. Proc Natl Acad Sci. USA. 1995;92(16):7202-6.

Ueda N, Kaushal GP, Shah SV. Apoptotic mechanisms in acute renal failure. Am J Med. 2000;108(5):403-15.

Valle BL, D´Souza T, Becker KG, Wood WH 3rd, Zhang Y, Wersto RP, Morin PJ. Non- steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells. PloS One. 2013;8(4):e61836.

Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232-5.

Vane JR, Botting RM. Mechanism of action of nonsteroidal antinflammatory drugs. Am J Med. 1998;104(3A):2S-8S.

Vermes I, Haanen C, Steffens-Nakken H, Reutelinqsperqer C. A novel assay for apoptosis. Flow citometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled anexin V. J Immunol Methods. 1995;184(1):34-51. Volpato G. Ciência: da Filosofia à Publicação. 5a Ed. São Paulo: Editora Cultura Acadêmica;2007.

Wang D, Dobois RN. Prostaglandins and Cancer. Gut. 2006;55(1):115-22

Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther. 2000;7(3):159-75.

Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci. USA. 1991;88(7):2692-6.

Yu L, Chen M, Li Z, Wen J, Fu J, Guo D, Jiang Y, Wu S, Cho CH, Liu S. Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation. Mol Pharmacol. 2011;79(3):608-17. Zadrazil J. Nonsteroidal antiinflammatory drugs and the kidney.Vnitr Lek. 2006;52(7- 8):686-90.